PHARMA IN BRIEF
Title: PHARMA IN BRIEF , Chemical Market Reporter, 00900907, 9/10/2001, Vol. 260, Issue 10
Section: Section 2 MARKETS: PHARMACEUTICALS & FINE CHEMICALS
ADVANCED PHARMA, a privately held specialty pharmaceutical company focused on the development of novel anti-infective products, is now called Advancis Pharmaceutical Corp.
ESTRADIOL The FDA has accepted Novavax Inc.’s new drug application for Estrasorb (17-beta-estradiol) lotion, a topical transdermal estrogen replacement therapy for symptomatic menopausal women. As a result, Novavax has received a $2.5 million milestone payment from King Pharmaceuticals Inc.
CELL GENESYS Inc. has completed the acquisition of Calydon Inc., a private biotechnology company focused on developing therapeutic products for cancer.
CIALIS Icos Corp.’s new drug application for Cialis, a treatment for erectile dysfunction, has been accepted by the FDA.
PHENTERMINE HYDROCHLORIDE Able Laboratories Inc. has received FDA approval for phentermine hydrochloride tablets USP, 37.5 mg, phentermine hydrochloride capsules USP, 30 mg, and phentermine hydrochloride capsules USP, 30 mg (beads).
SECRETIN The FDA has granted Fast Track designation for Repligen Corp.’s secretin for the treatment of pediatric autism.
Copyright of Chemical Market Reporter is the property of Schnell Publishing Company Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Chemical Market Reporter, 9/10/2001, Vol. 260 Issue 10, p8, 1p
